Stock

Kazia Therapeutics Limited KZIA

$12.31-5.23%

All stocks Create account to unlock

Overview

KZIA market data

Price History

KZIA price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for KZIA. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

8 captured

BTIG Reiterates Buy on Kazia Therapeutics, Maintains $34 Price Target · Jul 15, 2026, 5:20 PM

BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34 · Jul 1, 2026, 11:45 AM

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight · Jun 16, 2026, 5:15 PM

Lake Street Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $32 · Jun 11, 2026, 2:53 PM

Kazia Therapeutics Appoints James Levine as Chief Financial Officer · Jun 2, 2026, 12:15 PM

Kazia Therapeutics Appoints James Levine As CFO, Effective June 1 · Jun 2, 2026, 11:39 AM

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight · May 27, 2026, 5:15 PM

Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment Paxalisib · May 26, 2026, 11:36 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock